Summary
This 8-K filing from Johnson & Johnson announces a significant addition to its Board of Directors. Ronald A. Williams, former Chairman and CEO of Aetna Inc., has been appointed to the Board, effective June 13, 2011. Mr. Williams' extensive experience in the healthcare industry, particularly in leadership roles at a major insurance provider, is expected to bring valuable insights to JNJ's strategic direction and governance. His appointment signals a focus on strengthening the Board's expertise as the company navigates the complex healthcare landscape.
Key Highlights
- 1Johnson & Johnson appointed Ronald A. Williams, former Chairman and CEO of Aetna Inc., to its Board of Directors on June 13, 2011.
- 2Mr. Williams' appointment brings significant leadership and healthcare industry experience to the Board.
- 3He has been assigned to the Compensation & Benefits Committee and the Public Policy Advisory Committee.
- 4As a non-employee director, Mr. Williams' compensation is detailed in the 2011 Proxy Statement.
- 5Upon appointment, Mr. Williams received a one-time grant of 1,000 shares of unrestricted Common Stock at $67.06 per share.
- 6The filing includes a press release dated June 14, 2011, as an exhibit.
Frequently Asked Questions
Ronald A. Williams is the former Chairman and Chief Executive Officer of Aetna Inc. His appointment to Johnson & Johnson's Board of Directors is likely intended to leverage his extensive experience in the healthcare industry, particularly from a major health insurance perspective, to provide strategic guidance and oversight.
Mr. Williams has been appointed to serve on the Compensation & Benefits Committee and the Public Policy Advisory Committee of the Johnson & Johnson Board of Directors.
As a non-employee director, Mr. Williams receives compensation as outlined in Johnson & Johnson's 2011 Proxy Statement. This includes a one-time grant of 1,000 shares of unrestricted Common Stock at $67.06 per share upon his appointment.
While the appointment itself doesn't directly announce strategic changes, the addition of a seasoned executive from a key player in the healthcare ecosystem (Aetna) suggests a potential strengthening of the Board's focus on industry dynamics, policy, and executive compensation strategies.